Banking Recap

DarioHealth Corp. to Be Acquired

This deal involves a strategic review and potential sale process, classified as an M&A transaction in the healthcare sector, involving DarioHealth Corp. (ticker DRIO) as the target/subject company. The disclosed value of the transaction is not stated in the source document, consistent with the fact that this is a review process rather than a signed transaction with agreed terms.

Sep 25, 2025·SEC EDGAR (8-K)·pending regulatory·strategic review / potential sale process

The transaction is sourced from an 8-K filing with the SEC, filed via SEC EDGAR and published on September 25, 2025. The deal's current status is pending regulatory approval.

On the financial advisory side, Perella Weinberg Partners is identified as financial advisor to DarioHealth, in a lead capacity. The source material notes that in connection with this review, DarioHealth's Board of Directors established a Special Committee of independent directors and engaged Perella Weinberg Partners as financial advisor to assist with that process.

No legal advisors were extracted for this deal in the facts block, so it is not possible to state which law firms, if any, are advising the company or any potential counterparties in this process.

Beyond the engagement of a financial advisor to support a strategic review and potential sale process, no further detail on specific transaction terms, potential acquirers, or structural considerations is provided in the facts block, which is consistent with this being characterized as a review process rather than a definitive agreement.

Several material facts are not disclosed in the available record. No transaction value is stated, since no definitive transaction has been announced as of the facts given. No legal advisors are identified, no potential acquirer or counterparty is named, and no expected timeline or outcome for the strategic review is given beyond the pending-regulatory status noted in the September 2025 filing.